

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Raludotatug deruxtecan is an antibody-drug conjugate directed against ...
 - a. FR-alpha
 - b. CDH6**
 - c. HER2
 - d. XPO1
2. Which of the following outcomes was demonstrated by a preliminary biomarker assessment from the first-in-human study of raludotatug deruxtecan for patients with advanced or metastatic ovarian cancer not amenable to standard therapy?
 - a. Antitumor activity across a wide range of HER2 expression levels
 - b. Antitumor activity across a wide range of FR-alpha expression levels
 - c. Antitumor activity across a wide range of CDH6 expression levels**
3. The combination of avutometinib and defactinib is the first therapy to be granted FDA approval for which patient group?
 - a. Patients with newly diagnosed low-grade serous ovarian cancer
 - b. Patients with newly diagnosed low-grade serous ovarian cancer overexpressing HER2
 - c. Patients with recurrent low-grade serous ovarian cancer with a BRCA mutation
 - d. Patients with KRAS-mutated recurrent low-grade serous ovarian cancer**
4. Part 2 of the RUBY study demonstrated which of the following outcomes with first-line dostarlimab in combination with chemotherapy followed by dostarlimab and niraparib maintenance therapy for patients with primary advanced or recurrent endometrial cancer?
 - a. A progression-free survival (PFS) benefit in the mismatch repair-deficient (dMMR) patient population only
 - b. A PFS benefit in the mismatch repair-proficient (pMMR) patient population only
 - c. A PFS benefit in the dMMR and pMMR patient populations**
5. Which of the following HER2-targeted therapies is FDA approved for patients with previously treated metastatic endometrial or cervical cancer that is HER2 overexpressing (IHC 3+)?
 - a. T-DM1
 - b. Neratinib
 - c. Lapatinib/trastuzumab
 - d. Trastuzumab deruxtecan**